Shield appoints new Non-Exec Chairman
As announced within the FY19 results on 21 May 2020, James Karis, the company's current Chairman, notified the Board of his intention to step down at the AGM on 18 June and not seek re-election.
Hans Peter Hasler has therefore been appointed with effect from the AGM. Hans Peter joined Shield's Board of Directors in July 2018 and has served as Chairman of the Nomination Committee and a member of the Audit Committee.
Hans Peter has had prior executive experience including as Chief Operating Officer at both Elan Corporation and Biogen Inc. as well as Chief Marketing Officer of Wyeth Pharmaceuticals, Radnor, PA.
Currently, he is non-executive Chairman of the Board of HBM Healthcare Investments AG, Zug / Switzerland and a non-executive director of Minerva Neuroscience Inc., Boston. Mr. Hasler holds a Federal Swiss Commercial Diploma and a Marketing Manager Certificate from the Swiss Institute of Business Economy SIB, Zurich, Switzerland.
Shares in Shield have traded strongly off lows at the peek of the COVID-19 crisis of 54p to open flat today at 92p following this announcement.
Hans Peter Hasler said, "I am delighted to have been appointed as Chairman of Shield at a critical time for the Group. Feraccru®/ Accrufer® is an excellent product with enormous potential and I look forward to continuing to help the Group find ways of making it available to the widest possible number of patients and to translating that into value for shareholders. I also look forward to working with the rest of the Board and the management team in these endeavours."
Tim Watts, CEO of Shield Therapeutics, said: "I am very pleased to see Hans Peter appointed as our Chairman. I have worked increasingly closely with Hans Peter over the last two years and value his experience and insights and the support he has given me personally."
Follow News & Updates from Shield Therapeutics here:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.